Related Articles
Les Restaurants Lafleur – Fresh food, always served fast!
Craving something delicious? Restaurant Lafleur has you covered with delivery, pick up and 17 locations throughout Montreal, and beyond. Bite into happiness!
I can truly see the case for assisted dying. But the horrific state of the NHS makes me question if it is the best idea | Rachel Clarke
I would feel deeply uncomfortable if patients ‘chose’ to die because care that would make life worth living was unavailable, says palliative care doctor Rachel…
When frogs can’t croak to get a mate, they dance
“Foot-flagging” species tap into innate fright response to scare away rivals
Role of GLR-1 in Age-Dependent Short-Term Memory Decline
As the global elderly population grows, age-related cognitive decline is becoming an increasingly significant healthcare issue, often leading to various neuropsychiatric disorders. Among the many…
Boss Fighters Airdrop
Dive into the BOSS FIGHTERS Airdrop! Simply sign up using your X account and participate in daily social tasks. Earn BF coins for activities like…
Psychedelic skepticism: back to the sixties? – Eduardo Ekman Schenberg, 2024
The call for rigor by van Elk and Fried 1 is a welcome contribution to psychedelic research. The authors emphasized the well-known principles of internal,…
First cancer jab trial finds they ‘weaponise immune system to attack tumours’
A NEW mRNA cancer vaccine can reprogram the immune system to attack tumours within 48 hours, a study shows. The first-ever human clinical trial of…
Impact of the disruption in supply of varenicline since 2021 on smoking cessation in England: A population study
Addiction is an SSA journal publishing peer-reviewed research reports on pharmalogical and behavioural addictions spanning many different disciplines.
Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Landgren on MRD as an End Point for Multiple Myeloma Trials
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and…